In vitro basic fibroblast growth factor (bFGF) delivery using an antithrombogenic 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer coated with a micropatterned diamond-like carbon (DLC) film

Kenta Bito, Terumitsu Hasebe, Shunto Maegawa, Tomoki Maeda, Tomohiro Matsumoto, Tetsuya Suzuki, Atsushi Hotta

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In this study, a newly designed drug-release platform composed of an antithrombogenic 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer was introduced, which was impregnated with basic fibroblast growth factor (bFGF) (bFGF/MPC polymer) to enhance the endothelial cell activation. The platform was also coated with an ultrathin micropatterned diamond-like carbon (DLC) film (DLC/bFGF/MPC polymer) to precisely control the drug release rate and the cell compatibility. The resulting DLC/bFGF/MPC polymer could effectively prolong the bFGF release rate by depositing the micropatterned DLC. The number of adherent platelets on the DLC/bFGF/MPC polymer was significantly lower (about 1/14) than that on a currently used stent made of stainless steel (SUS316L), indicating the enhanced antithrombogenicity in the DLC/bFGF/MPC polymer. The proliferation of endothelial cells on the DLC/bFGF/MPC polymer and the DLC/MPC polymer (without bFGF) were also examined. It was found that the optical density of HUVEC on the DLC/bFGF/MPC polymer determined by WST-8 assay was higher by 25%than that on the DLC/MPC polymer (without bFGF) measured after 72 h of incubation. Our results suggest that the released bFGF that contributes to the expression of other growth factors results in the early proliferation of the HUVEC on the DLC/bFGF/MPC polymer.

Original languageEnglish
JournalJournal of Biomedical Materials Research - Part A
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Diamond like carbon films
Fibroblast Growth Factor 2
Fibroblasts
Polymers
Diamonds
Diamond
Carbon
Endothelial cells
Intercellular Signaling Peptides and Proteins
2-methacryloyloxyethyl phosphorylcholine
Stents
Density (optical)
Platelets

Keywords

  • BFGF
  • Biocompatibility
  • DLC
  • Drug release
  • MPC

ASJC Scopus subject areas

  • Ceramics and Composites
  • Biomaterials
  • Biomedical Engineering
  • Metals and Alloys

Cite this

@article{97f3fa53e9734af2a7f27051ba11725c,
title = "In vitro basic fibroblast growth factor (bFGF) delivery using an antithrombogenic 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer coated with a micropatterned diamond-like carbon (DLC) film",
abstract = "In this study, a newly designed drug-release platform composed of an antithrombogenic 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer was introduced, which was impregnated with basic fibroblast growth factor (bFGF) (bFGF/MPC polymer) to enhance the endothelial cell activation. The platform was also coated with an ultrathin micropatterned diamond-like carbon (DLC) film (DLC/bFGF/MPC polymer) to precisely control the drug release rate and the cell compatibility. The resulting DLC/bFGF/MPC polymer could effectively prolong the bFGF release rate by depositing the micropatterned DLC. The number of adherent platelets on the DLC/bFGF/MPC polymer was significantly lower (about 1/14) than that on a currently used stent made of stainless steel (SUS316L), indicating the enhanced antithrombogenicity in the DLC/bFGF/MPC polymer. The proliferation of endothelial cells on the DLC/bFGF/MPC polymer and the DLC/MPC polymer (without bFGF) were also examined. It was found that the optical density of HUVEC on the DLC/bFGF/MPC polymer determined by WST-8 assay was higher by 25{\%}than that on the DLC/MPC polymer (without bFGF) measured after 72 h of incubation. Our results suggest that the released bFGF that contributes to the expression of other growth factors results in the early proliferation of the HUVEC on the DLC/bFGF/MPC polymer.",
keywords = "BFGF, Biocompatibility, DLC, Drug release, MPC",
author = "Kenta Bito and Terumitsu Hasebe and Shunto Maegawa and Tomoki Maeda and Tomohiro Matsumoto and Tetsuya Suzuki and Atsushi Hotta",
year = "2017",
doi = "10.1002/jbm.a.36201",
language = "English",
journal = "Journal of Biomedical Materials Research",
issn = "1549-3296",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - In vitro basic fibroblast growth factor (bFGF) delivery using an antithrombogenic 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer coated with a micropatterned diamond-like carbon (DLC) film

AU - Bito, Kenta

AU - Hasebe, Terumitsu

AU - Maegawa, Shunto

AU - Maeda, Tomoki

AU - Matsumoto, Tomohiro

AU - Suzuki, Tetsuya

AU - Hotta, Atsushi

PY - 2017

Y1 - 2017

N2 - In this study, a newly designed drug-release platform composed of an antithrombogenic 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer was introduced, which was impregnated with basic fibroblast growth factor (bFGF) (bFGF/MPC polymer) to enhance the endothelial cell activation. The platform was also coated with an ultrathin micropatterned diamond-like carbon (DLC) film (DLC/bFGF/MPC polymer) to precisely control the drug release rate and the cell compatibility. The resulting DLC/bFGF/MPC polymer could effectively prolong the bFGF release rate by depositing the micropatterned DLC. The number of adherent platelets on the DLC/bFGF/MPC polymer was significantly lower (about 1/14) than that on a currently used stent made of stainless steel (SUS316L), indicating the enhanced antithrombogenicity in the DLC/bFGF/MPC polymer. The proliferation of endothelial cells on the DLC/bFGF/MPC polymer and the DLC/MPC polymer (without bFGF) were also examined. It was found that the optical density of HUVEC on the DLC/bFGF/MPC polymer determined by WST-8 assay was higher by 25%than that on the DLC/MPC polymer (without bFGF) measured after 72 h of incubation. Our results suggest that the released bFGF that contributes to the expression of other growth factors results in the early proliferation of the HUVEC on the DLC/bFGF/MPC polymer.

AB - In this study, a newly designed drug-release platform composed of an antithrombogenic 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer was introduced, which was impregnated with basic fibroblast growth factor (bFGF) (bFGF/MPC polymer) to enhance the endothelial cell activation. The platform was also coated with an ultrathin micropatterned diamond-like carbon (DLC) film (DLC/bFGF/MPC polymer) to precisely control the drug release rate and the cell compatibility. The resulting DLC/bFGF/MPC polymer could effectively prolong the bFGF release rate by depositing the micropatterned DLC. The number of adherent platelets on the DLC/bFGF/MPC polymer was significantly lower (about 1/14) than that on a currently used stent made of stainless steel (SUS316L), indicating the enhanced antithrombogenicity in the DLC/bFGF/MPC polymer. The proliferation of endothelial cells on the DLC/bFGF/MPC polymer and the DLC/MPC polymer (without bFGF) were also examined. It was found that the optical density of HUVEC on the DLC/bFGF/MPC polymer determined by WST-8 assay was higher by 25%than that on the DLC/MPC polymer (without bFGF) measured after 72 h of incubation. Our results suggest that the released bFGF that contributes to the expression of other growth factors results in the early proliferation of the HUVEC on the DLC/bFGF/MPC polymer.

KW - BFGF

KW - Biocompatibility

KW - DLC

KW - Drug release

KW - MPC

UR - http://www.scopus.com/inward/record.url?scp=85030157740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030157740&partnerID=8YFLogxK

U2 - 10.1002/jbm.a.36201

DO - 10.1002/jbm.a.36201

M3 - Article

JO - Journal of Biomedical Materials Research

JF - Journal of Biomedical Materials Research

SN - 1549-3296

ER -